Loading
companiesCompany
Adaptive Biotechnologies
Adaptive Biotechnologies makes clonoSEQ, the FDA-cleared sequencing test that finds one leukaemia cell in a million and now guides treatment in ALL, myeloma, and CLL.
Overview
Adaptive Biotechnologies, based in Seattle and listed as ADPT, makes clonoSEQ, the FDA-cleared sequencing test that finds one leukaemia cell in a million and now guides treatment in acute lymphoblastic leukaemia, myeloma and chronic lymphocytic leukaemia. clonoSEQ sequences IGH, IGK, IGL and T-cell receptor clonotypes and was the first FDA-cleared next-generation sequencing test for measurable residual disease, in 2018 for ALL and myeloma and in 2020 for CLL; it serves as the MRD endpoint in trials and in routine practice, and the company also runs the T-Detect immune medicine business. OnCo links it to NGS-based MRD testing, to the bottleneck of dormant cells and minimal residual disease, and to ideas on reference materials for residual disease tests. Whether MRD can become a regulatory endpoint for approval is the open question. clonoSEQ has its own page.
Headquarters
Seattle, WA, US
Scorecard
All companies#305of 1244 companies, score 13
- approved products +6
- modalities +2
- regions +1
- registry trials +4
1 approved, 0 in phase 3, 0 earlier, 0 targets, 4 registry studies. Formula on the scorecards page.
Type
Diagnostics · ADPT
Stage
Public
Website
ApprovedNGS minimal residual disease test (immunoglobulin and T-cell receptor clonotypes)
clonoSEQ · clonoSEQ
A DNA test that counts leftover leukaemia, myeloma or lymphoma cells down to one in a million, used to decide whether treatment has really worked.
Similar pages
- TrialMeasurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance
Shares clonoSEQ, Multiple myeloma.
- CompanyForesight Diagnostics
Shares Reference materials and open proficiency testing for residual disease tests, Dormant cells and minimal residual disease, MRD / molecular residual disease testing.
- TermMRD-negative complete remission
Shares clonoSEQ, NGS-based MRD (clonoSEQ and molecular MRD), Dormant cells and minimal residual disease, MRD / molecular residual disease testing.
- TermUndetectable MRD (uMRD / MRD-negative)
Shares clonoSEQ, MRD / molecular residual disease testing, Chronic lymphocytic leukaemia, Acute lymphoblastic leukaemia.
- IdeaA dedicated clinic for people whose blood test says the cancer is back
Shares Dormant cells and minimal residual disease, MRD / molecular residual disease testing.
- IdeaBlunt the inflammation that wakes sleeping cancer cells
Shares Dormant cells and minimal residual disease, MRD / molecular residual disease testing.
- TermMRD negativity (myeloma, 10⁻⁵ / 10⁻⁶)
Shares clonoSEQ, Dormant cells and minimal residual disease, MRD / molecular residual disease testing, Multiple myeloma.
- IdeaTake the blood test, and give the drug, at the right time of day
Shares Dormant cells and minimal residual disease, MRD / molecular residual disease testing.
cancers
fronts
technologies
drugs
ApprovedNGS minimal residual disease test (immunoglobulin and T-cell receptor clonotypes)
clonoSEQ · clonoSEQ